You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKesson
Johnson and Johnson
Baxter
Express Scripts

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

DEFERIPRONE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for deferiprone and what is the scope of patent protection?

Deferiprone is the generic ingredient in two branded drugs marketed by Chiesi and Taro Pharm Inds Ltd, and is included in four NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has forty-three patent family members in twenty-five countries.

There are four drug master file entries for deferiprone. Three suppliers are listed for this compound.

Recent Clinical Trials for DEFERIPRONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
First Affiliated Hospital of Fujian Medical UniversityEarly Phase 1
David HasanPhase 2
Ministry of Health, FrancePhase 2/Phase 3

See all DEFERIPRONE clinical trials

Pharmacology for DEFERIPRONE
Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Paragraph IV (Patent) Challenges for DEFERIPRONE
Tradename Dosage Ingredient NDA Submissiondate
FERRIPROX TABLET;ORAL deferiprone 021825 2016-01-29

US Patents and Regulatory Information for DEFERIPRONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds Ltd DEFERIPRONE deferiprone TABLET;ORAL 208800-001 Feb 8, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Harvard Business School
Moodys
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.